Navigation Links
DiagnoCure announces fourth quarter 2008 and year-end results
Date:12/17/2008

DiagnoCure's non-invasive bladder cancer test, ImmunoCyt(TM) / uCyt+(TM), were $65,402 for the fourth quarter of 2008 versus $79,085 for the same period a year ago. Also in this quarter, DiagnoCure sold clinical samples to Gen-Probe, in support of their prostate cancer testing R&D, for an amount of $58,441 compared with $13,911 in the fourth quarter of 2007.

Interest income decreased $90,269 to $267,659 for the fourth quarter of 2008 compared with $357,928 for the fourth quarter of 2007. The decrease is attributable to DiagnoCure's use of fund to finance the operating activities and the reduction of interest yield in its investments.

Cost of sales increased $15,819 from $62,875 for the fourth quarter of 2007 to $78,694 for the fourth quarter of 2008. This increase is related to higher samples sales.

Based on the above, for the fourth quarter of 2008, DiagnoCure recorded a net loss of $3,568,321, or $0.09 per share, compared with a loss of $3,320,193, or $0.09 per share, for the fourth quarter of 2007. These results are substantially in line with Management expectations and reflect the sales and marketing activities that led to the launch of the Previstage(TM) GCC test in late summer 2008 and the first orders of the test.

    Financial data

    -------------------------------------------------------------------------
                              Three months ended             Years ended
    For the periods of            October 31                  October 31
                       ------------------------------------------------------
                              2008          2007          2008          2007
    -------------------------------------------------------------------------
    Sales                  123,843        94,129       524,564       432,763
    -------------------------------------------------------------------------
    Revenue under
     research and
     license agreeme
'/>"/>
SOURCE DIAGNOCURE INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. DiagnoCures molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings
2. DiagnoCure to host Q2 2008 earnings conference call and webcast
3. DiagnoCure announces second quarter 2008 results
4. DiagnoCures GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Group
5. Diagnocure announces sponsorship of inaugural undy 5,000 run - Partnership with the Colon Cancer Alliance creates patient awareness of previstage(TM) GCC staging test
6. DiagnoCure to present at the JMP Securities Healthcare Focus Conference on October 6, 2008
7. DiagnoCure to webcast presentation at the Piper Jaffray Health Care Conference on December 3, 2008
8. DiagnoCure announces fourth quarter and full year 2008 earnings conference call and webcast
9. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
10. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
11. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... Ticket Down is a reputable source for authentic ... Center. After being away from the touring business for ... of letting up on his “Garth Brooks World Tour.” The ... Yearwood, to venues around the United States. The duo recently ... to the Moda Center in Portland, OR. The husband and ...
(Date:3/6/2015)... As the Muscular Dystrophy Association continues ... organization has hired two new Scientific Program Officers, Amanda ... report to Grace Pavlath, Ph.D, who joined MDA late ... Director, and together will lead MDA as it accelerates ... for various types of neuromuscular and motor neuron diseases. ...
(Date:3/6/2015)... CA (PRWEB) March 06, 2015 US ... of three Maryland camps – two non-contact specialty camps ... be run by Perfect Performance Training, located at Bowie ... focus on developing position specific skills, speed and strength ... hosted at Salisbury University with Marvin Graves, former quarterback ...
(Date:3/6/2015)... Johnson & Johnson and Ethicon were hit ... 2015 in Superior Court in the State of California ... of 12 awarded Mrs. Perry $700,000 in actual damages ... Ethicon TVT Abbrevo plastic sling for stress urinary incontinence. ... awarded $5 million in punitive damages. , According to ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Jvion, ... the release of a Clostridium Difficile (C Diff) ... The C Diff use case is the latest ... span hospital acquired infections, chronic conditions, and individual ... the C Diff solution flags at risk individuals ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
... could bring new treatment options for patients, researchers ... Surgery patients may one day find nicotine patches ... pad, researchers say. , Nicotine patches and the ... surgery, according to two studies presented at the ...
... Texas, 181,legislators are being honored with the Texas ... on behalf of health care,during the 80th Session ... the award in 1997 to honor state legislators ... issues important,to hospitals and health systems. Recipients ...
... Arthur H. Rubenstein,MBBCh, executive vice president for the health ... Dunlop professor of medicine at the University,of Pennsylvania, has ... the,Association of Academic Health Centers., Dr. Rubenstein served ... New,York before assuming his current position at the University ...
... stomach risks, study notes , , MONDAY, Oct. 15 ... their doctors that they take common over-the-counter painkillers, such ... new study has found. , "With nearly one out ... no wonder that adverse events are increasing yearly," said ...
... 15 /PRNewswire/ - Neuromed,Pharmaceuticals, a biopharmaceutical company developing ... has successfully reached an,agreement with the U.S. Food ... (SPA) process for the planned pivotal Phase 3,clinical ... of,chronic pain. A SPA is a procedure by ...
... Edwards Lifesciences,Corporation (NYSE: EW ), a global ... plans to announce its operating,results for the quarter ended ... 22, 2007 and will host a conference call at ... To participate in the conference call, dial (877) 407-8037 ...
Cached Medicine News:Health News:Nicotine, Chili Peppers Offer Post-Surgery Pain Relief 2Health News:Nicotine, Chili Peppers Offer Post-Surgery Pain Relief 3Health News:THA Honors Nine Legislators for Contributions to Health Care 2Health News:Association of Academic Health Centers Names University of Pennsylvania's Dr. Arthur H. Rubenstein Chairman of the Board of Directors 2Health News:Many Patients Don't Report Use of OTC Pain Drugs 2Health News:Many Patients Don't Report Use of OTC Pain Drugs 3Health News:Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077 2Health News:Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077 3Health News:Edwards Lifesciences to Host Earnings Conference Call on October 22, 2007 2
(Date:3/6/2015)... 6, 2015  The German Court of Appeal has ruled ... vitamin regimen patent for Alimta® (pemetrexed disodium) would not be ... dipotassium salt form of pemetrexed in Germany ... The German Court ruled in favor of the ... v. Actavis. This decision vacated the prior decision of the ...
(Date:3/6/2015)... 6 de marzo de 2015 TeraRecon, ... gestión empresarial de imagen médica, fortalece su posición ... de Randolph Sternberg como director de ... director de operaciones. Logo - ... será responsable de las ventas y desarrollo empresarial ...
(Date:3/6/2015)... , March 6, 2015 ... des cohortes de patients pouvant bénéficier de l,innovation ... des solutions d,enrichissement sémantique de contenu pour l,Entreprise, ... par UNICANCER, Groupe des Centres de lutte contre ... cadre de son projet ConSoRe (Continuum Soin-Recherche) conduit ...
Breaking Medicine Technology:German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit 2German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit 3TeraRecon fortalece su posición en EMEA 2TeraRecon fortalece su posición en EMEA 3TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 2TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 3TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 4
... voluntary recall of ALL lots of its Ketorolac Tromethamine Injection, USP ... NDC# 0517-0601-25 15 mg/mL ... This recall is in addition to the voluntary recall initiated on ... unexpired lots of Ketorolac Tromethamine Injection, USP, 30 mg/mL ...
... a next-generation oncology diagnostics company focused on improving ... closed a $21 million series A financing. ... and included Bessemer Venture Partners, Physic Ventures and ... ) , On-Q-ity is developing diagnostics to determine ...
Cached Medicine Technology:American Regent Expands Voluntary Recall to Include All Lots of Ketorolac Tromethamine Injection, USP 15 mg/mL; 1mL Single Dose Vials 2Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy 2
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours....
... Portex® Thermovent® T helps provide protection to the ... small and extremely lightweight making it ideal for ... a high rate of heat and moisture recovery, ... ,All HMEs and filters have ISO standard ...
This adjustable-volume digital micropipet is used to accurately measure and transfer small solution volumes in the 20-200 microliter range....
Medicine Products: